CAH

Business profile & competitive position

Cardinal Health, Inc. (CAH) operates in the Healthcare sector, specifically the Medical – Distribution industry. In plain terms, it runs a wholesale/service layer between drug manufacturers, medical-product makers, hospitals, pharmacies, physicians, and payers. The company reports through two large segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD), plus smaller “Other” operations.

The economics of that model are visible in the headline numbers. Fiscal 2026 revenue reached $254.2 billion, up 14%, with the Pharma segment alone contributing $234.8 billion, up 15%. Yet net margin is only 0.7%. That near-zero margin is textbook for large-scale healthcare distribution: the competitive moat comes from logistics density, contract lock-in, and scale purchasing rather than pricing power at the customer level. Meanwhile, ROE is reported at -59.7%, a deeply negative figure that generally reflects negative or very low shareholders’ equity after years of buybacks and earnings-driven balance-sheet changes rather than weak cash generation in the current year. Investors should read ROE here as a balance-sheet artifact, not necessarily a profitability signal.

Financial posture

Cardinal’s current market cap is $58.8 billion, its trailing P/E is 34.9, and its beta is 0.50. The low beta fits the non-discretionary nature of pharmaceutical distribution, but the P/E sits well above what one might expect from a sub-1% net-margin distributor. That combination suggests the market is valuing the company on growth in specialty pharma services, margin expansion, and capital-return credibility rather than raw earnings yield.

The profitability backdrop is mixed. Fiscal 2026 non-GAAP operating earnings rose 30% to $3.6 billion, while GAAP operating earnings rose 15% to $2.6 billion. So operating leverage is real, but the gap between the GAAP and non-GAAP figures is wide enough that analysts typically dig into which charges are recurring. The stock is trading around $253.78, with a 50-day EMA of $239.91 and an RSI of 62.1, showing it has outpaced its short-term moving average without yet pushing into extreme overbought territory.

Strategic priorities & outlook

Cardinal’s most recent 10-K lays out four near-term operational priorities. First, it plans to expand and integrate the Specialty Alliance multi-specialty MSO platform and other acquired physician-practice support platforms to capture expected value. The company closed the Solaris Health urology-MSO purchase on November 3, 2025, for roughly $1.9 billion, and afterward owned approximately 76% of The Specialty Alliance. That deal is central to the strategy of moving beyond pure distribution and into higher-touch specialty care services.

Second, management is working to reduce tariff impacts in GMPD through cost optimization and by raising prices on affected products. Third, the company will continue to manage its Pharma generics program, including product launches, customer volumes, pricing, Red Oak Sourcing, and contract manufacturing/sourcing costs. Fourth, Cardinal is targeting approximately $700 million in fiscal 2027 capital expenditures, directed at manufacturing, distribution infrastructure, and technology.

Putting those priorities together, the 10-K story is a mix of top-line muscle (Pharma volume + Specialty acquisitions), margin defense (tariff pass-through and generics sourcing), and capacity investment.

Macro & geopolitical exposure

As a global medical distributor, Cardinal sits in the cross-currents of several macro forces. Because GMPD sources and sells medical products internationally, tariffs and trade policy directly affect landed costs and pricing flexibility; the company has already flagged tariff mitigation as an operational focus. On the Pharma side, drug-pricing legislation—including Medicare price negotiations and rebate rules—can compress or shift branded and generic profit pools. Generic deflation remains a constant pressure in pharmaceutical distribution, while specialty and biosimilar growth offers an offset through higher-touch, stickier services.

The business is also exposed to regulatory compliance (DEA opioid reporting, FDA medical-device logistics, state pharmacy licensing), supply-chain resilience (inventory availability, shipping constraints, China-based manufacturing exposure), and currency translation for non-dollar operations under the Global Medical Products segment. Healthcare utilization trends and payer mix add another layer, but unlike a hospital operator, Cardinal’s revenue is more tied to product flow than to payer reimbursement rates alone.

Recent developments

• November 2, 2026 (Zacks): “What Analyst Projections for Key Metrics Reveal About Cardinal (CAH) Q1 Earnings”
• November 2, 2026 (Zacks): “Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?”
• October 27, 2026 (Zacks): “Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade”
• October 23, 2026 (Seeking Alpha): “The Dividend Aristocrats Ranked By Quality Scores (October 2026)”

The Zacks pieces frame the immediate debate: whether Cardinal’s specialty and Pharma momentum can offset sluggishness on the medical distribution side ahead of the Q1 report. The Seeking Alpha headline reminds income-focused investors that CAH is still tracked among Dividend Aristocrats, so capital-allocation consistency remains part of the narrative.

Earnings behavior & post-earnings drift

Cardinal’s earnings track record is statistically unusual, and it illustrates why “beat = pop” is not a reliable rule. Over the last eight reported quarters, CAH has beaten estimates 8 out of 8 times (100%), with an average earnings surprise of 12.5%. Yet the average 5-day price move after those reports is -1.8%, classified as a downward post-earnings drift. The message is that the market has regularly expected the company to exceed estimates, and by the time the results print, much of that upside has already been priced in.

The last four quarters show the pattern clearly:

• August 11, 2026: EPS $2.91 vs. estimate $2.42, a 20.2% surprise — stock fell 2.54% the next day and 2.2% over the following five days.
• April 30, 2026: EPS $3.17 vs. estimate $2.79, a 13.6% surprise — next-day gain of 1.22%, but a 5-day decline of 3.94%.
• February 5, 2026: EPS $2.63 vs. estimate $2.34, a 12.4% surprise — stock slipped 0.38% the next day and 5.33% over the next week.
• October 30, 2025: EPS $2.55 vs. estimate $2.18, a 17.0% surprise — a modest 0.49% next-day gain, and the only one of the four with a positive five-day drift, up 4.29%.

With the next report scheduled for November 5, 2026, before the open, and the consensus EPS estimate at $2.94, the relevant question is not just whether Cardinal will beat but whether the size of any beat clears the unofficial consensus that has already been built into the price.

For a deeper dive into how institutional analysts and the options market are currently positioned around CAH, explore the full institutional verdict on the ticker page.